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Loss-of-Function Myeloperoxidase Mutations
Are Associated with Increased Neutrophil Counts
and Pustular Skin Disease
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The identification of disease alleles underlying human autoinflammatory diseases can provide important insights into the mechanisms
that maintain neutrophil homeostasis. Here, we focused our attention on generalized pustular psoriasis (GPP), a potentially life-threat-
ening disorder presenting with cutaneous and systemic neutrophilia. Following the whole-exome sequencing of 19 unrelated affected
individuals, we identified a subject harboring a homozygous splice-site mutation (c.20312A>C) in MPO. This encodes myeloperoxi-
dase, an essential component of neutrophil azurophil granules. MPO screening in conditions phenotypically related to GPP uncovered
further disease alleles in one subject with acral pustular psoriasis (c.20312A>C;c.20312A>C) and in two individuals with acute gener-
alized exanthematous pustulosis (c.1705C>T;c.20312A>C and c.1552_1565del;c.1552_1565del). A subsequent analysis of UK Biobank
data demonstrated that the c.20312A>C and c.1705C>T (p.Arg569Trp) disease alleles were also associated with increased neutrophil
abundance in the general population (p ¼ 5.1 3 106 and p ¼ 3.6 3 105, respectively). The same applied to three further deleterious
variants that had been genotyped in the cohort, with two alleles (c.995C>T [p.Ala332Val] and c.752T>C [p.Met251Thr]) yielding p
values< 1010. Finally, treatment of healthy neutrophils with anMPO inhibitor (4-Aminobenzoic acid hydrazide) increased cell viability
and delayed apoptosis, highlighting a mechanism wherebyMPOmutations affect granulocyte numbers. These findings identifyMPO as
a genetic determinant of pustular skin disease and neutrophil abundance. Given the recent interest in the development of MPO antag-
onists for the treatment of neurodegenerative disease, our results also suggest that the pro-inflammatory effects of these agents should be
closely monitored.A tight regulation of neutrophil numbers is crucial to
innate immune homeostasis. As mature granulocytes do
not divide, their accumulation depends on the balance be-
tween progenitor proliferation, release of differentiated
cells into the bloodstream, and clearance of aging cells.1
Given the difficulty of manipulating primary neutrophils,
the mechanisms that regulate these processes have mostly
been investigated in animal models. In this context, the
genetic characterization of human autoinflammatory dis-
eases can provide crucial insights into the pathways that
maintain neutrophil homeostasis.
Here we focused our attention on generalized pustular
psoriasis (GPP [MIM: 614204]), a potentially life-threat-
ening condition presenting with flares of neutrophilic
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GmbH, Biberach 88397, Germany; 15Boehringer-Ingelheim Pharmaceuticals,





 2020 The Author(s). This is an open access article under the CC BY licenseproduction of acute phase reactants, and neutrophilia.
While disease alleles have been described in IL36RN,
AP1S3, and CARD14, the majority of affected individuals
do not carry deleterious changes at these loci.2
To identify genetic determinants for GPP, we undertook
whole-exome sequencing in 19 unrelated affected individ-
uals of varying ancestry (Table S1, Figure 1A). Given the
severity of the condition and the lack of parent-offspring
transmissions, we hypothesized the presence of recessive
loss-of-function alleles. We therefore filtered the variant pro-
files to retain rare homozygous changes predicted to cause
premature protein truncation. This identified six candidate
mutations, each affecting a single individual (Table S2).
The c.20312A>C substitution in MPO (MIM: 606989;
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Figure 1. MPO Mutations Are Associated with Pustular Skin Disease
(A) Typical presentation of generalized pustular psoriasis (bottom panel, showing skin pustulation on an erythematous background) and
acral pustular psoriasis (top panel, showing neutrophil-filled pustules affecting the soles).
(B) Validation of the disease alleles identified by whole-exome sequencing. The chromatograms show the c.20312A>C substitution
observed in the GPP and APP subjects (left) and the c.1552_1565del deletion detected in a study participant with AGEP (right). The po-
sition of disease alleles is highlighted by bold, underlined font. Sanger sequencing could not be carried out in the
c.20312A>C;c.1705C>T individual as no DNA was left for this subject.follow-up, as the gene encodes myeloperoxidase, a major
component of neutrophil azurophilic granules. Of note,
the c.20312A>C change has been previously observed
in individuals presenting with myeloperoxidase deficiency
(MPOD [MIM: 254600]) (Table S3), an inherited defect of
neutrophil microbicidal activity.3 Specifically, Marchetti
et al. demonstrated that the substitution affects splicing
and leads to the production of a truncated protein lacking
enzymatic activity.3
Here, the frequency of the c.20312C;c.20312C geno-
type among European GPP case subjects was much higher
than that observed in the non-Finnish European exomes
sequenced by the gnomAD consortium (5.3% versus
0.003%; p ¼ 0.001) (Table 1). Given that frequency esti-
mates obtained in small datasets are not always robust,
the MPO coding region was next examined in a validation
sample, including 14 GPP subjects and 109 individuals
with acral variants of pustular psoriasis (APP). This uncov-
ered a further study participant harboring a homozygous
c.20312A>C substitution (Figure 1B, Table 2, and Supple-
mental Note).
While no other bi-allelic or truncating MPO changes
were detected (Table S4), a comparison of the replication
cohort against a second gnomAD dataset (32,264 Non-
Finnish European genomes) confirmed the elevated fre-
quency of the c.20312C;c.20312C genotype in case
subjects versus control subjects (0.8% versus 0%; p ¼
0.004) (Table 1). Finally, the analysis of the combined
study resource (142 case subjects versus 89,010 control
subjects) yielded a p value of 1.5 3 105 (Table 1). Impor-
tantly, the c.20312C;c.20312C genotype was also ab-
sent from 590 British exomes processed with our in-house
pipeline. Thus, the association with GPP/-APP is unlikely
to be a technical artifact or to reflect population stratifica-
tion between case and control subjects.540 The American Journal of Human Genetics 107, 539–543, SeptemTo further investigate the impact of MPO recessive
alleles, we queried exome-sequencing data available for
96 unrelated individuals affected by acute generalized
exanthematous pustulosis (AGEP). This is a severe cuta-
neous adverse reaction, which can be triggered by drugs
(mostly antibiotics and antifungals), leading to flares of
skin pustulation, fever, and systemic neutrophilia.4 Our
analysis identified an affected individual, who was homo-
zygous for a 14 bp MPO deletion (c.1552_1565del
[p.Met519Profs*21]). A second study participant had
inherited the c.20312A>C substitution previously
observed in GPP/APP, in conjunction with a damaging
c.1705C>T (p.Arg569Trp) change (CADD score: 35.0)
(Table 2, Supplemental Note).
Of note, homozygous c.1705C>T (p.Arg569Trp) muta-
tions have been repeatedly observed in individuals affected
byMPOD.5,6 A c.1555_1568del variant, which overlaps the
c.1552_1565del variant described here, has also been docu-
mented in an affected-relative pair, where it triggered
nonsense-mediated decay in at least one individual7 (Table
S3). Thus, all theMPO alleles observed in our dataset have a
well-established impact on protein function.
MPOD is a mild immune deficiency that is clinically
well characterized. We therefore undertook a systematic
literature review, to better understand the connection
between MPO mutations, MPOD, and skin pustulation.
We examined 28 articles describing the presentation of
MPOD in 217 individuals. This uncovered four case
reports where the disease manifested with pustular erup-
tions and a fifth where it was associated with the severe
neutrophilic dermatosis known as pyoderma gangreno-
sum (Table S5). Given the very low prevalence of the above
conditions (<1:100,000), these observations strengthen
the link between MPO dysfunction and neutrophilic
inflammation.ber 3, 2020
Table 1. Frequency of the c.20312C;c.20312C Genotypes in Case Subjects versus Control Subjects
Genotype Counts (%)
p ValueCases Controls
Discovery cohort 1/19 (5.3%) 2/56,7466 (0.003%) 0.001
Replication cohort 1/123 (0.8%) 0/32,264 (0%) 0.004
Combined study cohort 2/142 (1.4%) 2/89,010 (0.002%) 1.5 3 105
c.20312A>C was the only truncating change observed in the homozygous state in the control subjects, obviating the need for a burden association test.To investigate the mechanisms whereby MPO mutations
contribute to disease, we explored the phenotypic effects
of the c.20312A>C variant though a Phenome-Wide
Association study (PheWAS). We queried the UK Biobank
dataset, which includes genotype information and
health data for a well-characterized population cohort
(>450,000 individuals).8 While the fraction of c.20312C
homozygotes (0.003%) (Table S3) present in the biobank
was very small, c.20312A>C heterozygotes accounted
for approximately 1% of study participants. Thus, we were
able to analyze the c.20312A>C genotypes against 778
available phenotypes. This revealed that the traits showing
the most significant associations with c.20312A>C were
related to leukocyte counts. In this context, the largest effect
size (beta) was observed for the association with neutrophil
abundance (beta¼ 0.45; p¼ 5.13 106; Figure 2A). To vali-
date these findings, we examined the c.1705C>T
(p.Arg569Trp) change and three additional MPOD alleles
(c.518A>G [p.Tyr173Cys], c.752T>C [p.Met251Thr],
c.995C>T [p.Ala332Val]) for which genotype data were
available in UK Biobank (Table S3). We found that all were
associated with increased neutrophil accumulation, with p
values ranging from 0.008 to 3.9 3 1028 (Figure 2B).
To explore the pathways underlying the effects of
MPO alleles on granulocyte numbers, we examined
RNA-sequencing profiles generated in pure neutrophil pop-
ulations (see Supplemental Subjects and Methods). Specif-
ically, we compared gene expression in the c.20312A>C
homozygous GPP individual versus 11 healthy control sub-
jects. We observed that MPO was expressed at comparable
levels in the affected subject and the unaffected control
subjects (FDR > 0.5). As c.20312A>C affects the splicing
of the last exon, this is in keeping with the expectation of
an escape from nonsense-mediated decay.Table 2. Disease Features Observed in Individuals with Bi-allelic MPO
Subjects Sex Age of Onset Diagnosisa
GYFAP0014 F 36 GPP
DDPLM0001 F 24 APP
SCAR2124 F 80 AGEP (methotrexate)
SCAR2567 F 69 AGEP (hydroxychloroquin
None of the affected individuals reported a history of recurrent infections.
aThe most likely culprit drug for each AGEP subject is reported in parentheses. AG
GPP, generalized pustular psoriasis.
The AmericanConversely, we found that 95 genes were upregulated in
the affected individual (FDR < 0.05) (Table S6). The major-
ity of these loci (85/95) were not overexpressed in 7 unre-
lated individuals with GPP (all MPO wild type) examined
in parallel, indicating that the changes are unlikely to be
a secondary effect of inflammation.
While the experiment was limited by the modest sample
size and the number of differentially expressed genes was
too small for pathway enrichment analyses, we noted
that two of the five most upregulated loci (PBK and GU-
CYA2) encode proteins (PDZ binding kinase and soluble
guanylate cyclase alpha-2 subunit) that can inhibit
apoptosis.9,10 This suggests thatMPOmutations may affect
neutrophil survival.
We investigated this possibility by using a myeloperoxi-
dase inhibitor (4-Aminobenzoic acid hydrazide, ABAH) to
mimic the effects of MPO disease alleles in cell culture ex-
periments. We induced neutrophil apoptosis through
Phorbol 12-myristate 13-acetate (PMA) stimulation and as-
sessed the effects of ABAH pre-treatment on this process.
While PMA caused substantial neutrophil death, we found
that ABAH supplementation caused an increase in cell
viability (Figure 2C) and a reduction in the number of
apoptotic cells (Figure 2D). Thus, neutrophil apoptosis is
downregulated in the absence of MPO activity.
Our findings (and those independently reported by
Haskamp et al.11) demonstrate a significant association be-
tweenMPOmutations and pustular skin disease. While the
disease alleles described here have also been implicated
in MPOD, we did not observe any evidence of immune
deficiency in the individuals examined in this study.
Likewise, pustular skin disease is present in only a fraction
of people affected by MPOD. Thus, it is tempting to
speculate that the manifestations of MPO mutationsMutations
Systemic Involvement Genotype
fever and neutrophilia c.20312A>C;c.20312A>C
– c.20312A>C;c.20312A>C
fever and neutrophilia c.1552_1565del;c.1552_1565del
e) fever c.20312A>C;c.1705C>T
EP, acute generalized exanthematous pustulosis; APP, acral pustular psoriasis;
Journal of Human Genetics 107, 539–543, September 3, 2020 541
Figure 2. MPO Mutations Are Associated with Increased Neutrophil Counts and Delayed Apoptosis
(A) Manhattan plot where each dot represents the association between c.20312A and a clinical trait. The p values for phenotypes
related to leukocyte counts are highlighted with a red circle and reported on the right, alongside the effect sizes (beta).
(B) Association between MPO deficiency alleles and neutrophil percentage. The size of each bubble represents the frequency of the mu-
tation in UK Biobank.
(C and D) ABAH pre-treatment of cells stimulated with PMA increases viability (C) and downregulates apoptosis (D). In (C) data are pre-
sented as the mean (5SD) of four experiments carried out in triplicate. In (D) each line represents an independent healthy donor. A
representative set of flow cytometry plots is shown on the left with the percentage of apoptotic cells (AnnexinVþ, PI- population) for
each condition. RPMI ¼ untreated (medium only); *p < 0.05 **p < 0.01; ***p < 0.001 (non-parametric ANOVA).may be influenced by background polygenic variation,
especially as a similar phenomenon has been documented
in rare hematological phenotypes.12 Of note, the
c.20312C;c.20312C GPP individual described here
also harbored a deleterious AP1S3 allele (GenBank:
NM_001039569.2; c.97C>T [p.Arg33Trp]),13 which
further supports the involvement of genetic modifiers.
An increased prevalence of spondyloarthropathy has
also been reported among individuals with MPO defi-
ciency.14 This suggests that the disruption of neutrophil
apoptosis may affect immune homeostasis in multiple or-
gans. Given that MPO inhibitors are being developed for
the treatment of neurodegenerative disease,15 our data sug-
gest that the inflammatory side effects of these agents
should be closely monitored during clinical trials.
The results of our PheWAS indicate that the effects of
MPO alleles are likely to be mediated by a systemic upregu-
lation of neutrophil numbers. Of note, a significant associ-
ation between granulocyte abundance and a commonMPO
variant has previously been documented,16 further sup-
porting the role of the gene in neutrophil homeostasis.
Further studies will be required to dissect the molecular
mechanisms whereby MPO deficiency downregulates
cell death. Given that PBK (one of the most upregulated
genes in the c.20312A>C homozygous individual) is an
inhibitor of myeloid cell apoptosis,9 its role is worthy of
further examination. A proposed link between MPO-542 The American Journal of Human Genetics 107, 539–543, Septemrelated oxidative stress, NF-kB activation, and apoptotic
signaling17 should also be investigated. While experimen-
tally demanding, these studies have the potential to illumi-
nate key regulators of innate immune homeostasis and un-
cover new candidate genes for neutrophilic conditions.Data and Code Availability
The neutrophil RNA-sequencing dataset described in this
study may be obtained from the Gene Expression
Omnibus using identifier GSE123787.Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
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